Therapy
Pembrolizumab
Monoclonal antibody targeting PD-1.
Also called: pembrolizumab, Keytruda, PD-1 inhibitor, pembro
In short
- 1What it is: a therapy in therapies and applications.
- 2How it connects: acts on 3 and is affected by 2 concepts — mostly 1 cell, 1 receptor, 2 trial.
- 3Where it sits: therapy, trial on the 15-step immune chain.
What it does
Humanised IgG4κ (stabilised to prevent Fab arm exchange); anti-PD-1; rescues progenitor exhausted CD8 CTLs (TCF-1+/PD-1+/TIM-3-); KEYnote-006 (melanoma): 5yr OS 38.7% vs 31.1% ipilimumab; FDA-approved 20+ tumour types; tumour-agnostic: MSI-H/dMMR (2017), TMB-H ≥10 mut/Mb (2020).
Its connections at a glance
Each dot is a concept directly linked to Pembrolizumab. Colours show the kind of concept.
Sources & evidenceloading…
Loading reviewed sources…
Graph ID I008 · concept status: established. Select any connection above to inspect evidence for that specific link.